Status:
COMPLETED
Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Schizophrenia
Tobacco Use Disorder
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an...
Detailed Description
There is a high prevalence of cigarette smoking among people with schizophrenia and few smoking cessation interventions have been developed for these individuals. Bupropion is an antidepressant medica...
Eligibility Criteria
Inclusion
- Diagnosed with schizophrenia or schizo-affective disorder
- Smokes between 20 and 50 cigarettes per day
- Moderate to high nicotine dependence score
- Interest in quitting smoking
Exclusion
- Currently trying to quit smoking
- Seizure disorder or lowered seizure threshold due to anorexia, bulimia, head trauma, diabetes with insulin, or hypoglycemics
- Alcohol or drug use disorders
- Requires certain medications
- Pregnant or breastfeeding
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00218231
Start Date
January 1 2004
End Date
August 1 2006
Last Update
January 12 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Providence VA Medical Center, RI
Providence, Rhode Island, United States, 02908
2
Brown University
Providence, Rhode Island, United States, 02912